SCHEMBL5172183

SCHEMBL5172183

PC(c1ccccc1)(c1ccccc1)C1CCCCC1C(P)(c1ccccc1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
CYP2D6 P10635 6/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
HRH1 P35367 2/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
SCN1A P35498 1/20 0.35
KMT2A Q03164 1/20 0.35
SCN2A Q99250 1/20 0.35
SCN3A Q9NY46 1/20 0.35
TSHR P16473 3/20 0.35
ALDH1A1 P00352 2/20 0.35
KCNN4 O15554 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3958141 1.00 KEAP1 (0.42) KEAP1NFE2L2CYP2D6KDM4ENPC1
SCHEMBL10448783 1.00 KEAP1 (0.42) KEAP1NFE2L2CYP2D6KDM4ENPC1
SCHEMBL8872460 0.95 KEAP1 (0.38) KEAP1NFE2L2CYP2D6KDM4ENPC1
SCHEMBL11454390 0.95 KEAP1 (0.38) KEAP1NFE2L2CYP2D6KDM4ENPC1
SCHEMBL11026818 0.95 KEAP1 (0.38) KEAP1NFE2L2CYP2D6KDM4ENPC1
SCHEMBL749097 0.90 KCNN4 (0.38) KEAP1NFE2L2CYP2D6KDM4ENPC1
SCHEMBL3502282 0.90 KCNN4 (0.38) KEAP1NFE2L2CYP2D6KDM4ENPC1
SCHEMBL27838356 0.84 KEAP1 (0.50) KEAP1NFE2L2CYP2D6HRH1MEN1
SCHEMBL5717261 0.82 KEAP1 (0.48) KEAP1NFE2L2CYP2D6HRH1MEN1
Bromide SCHEMBL11245316 0.80 KEAP1 (0.47) KEAP1NFE2L2CYP2D6HRH1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1299342-B1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SANOL ARZNEI SCHWARZ GMBH (DE) 2007-05-02 EP claimed
US-6809225-B2 BY HYDROCARBONYLATION/HYDROFORMYLATION WITH SUBSEQUENT REDUCTIVE AMINATION SCHWARZ PHARMA AG (DE) 2004-10-26 US claimed
US-20040034080-A1 Method for producing 3,3-diarylpropylamines UCB PHARMA GMBH (DE) 2004-02-19 US claimed
WO-2024127999-A1 METHOD FOR PRODUCING CYCLIC OLEFIN COMPOUND 三井化学株式会社 2024-06-20 WO disclosed
EP-1299342-B1 METHOD FOR PRODUCING 3,3-DIARYLPROPYLAMINES SANOL ARZNEI SCHWARZ GMBH (DE) 2007-05-02 EP disclosed
US-6809225-B2 BY HYDROCARBONYLATION/HYDROFORMYLATION WITH SUBSEQUENT REDUCTIVE AMINATION SCHWARZ PHARMA AG (DE) 2004-10-26 US disclosed
US-20040034080-A1 Method for producing 3,3-diarylpropylamines UCB PHARMA GMBH (DE) 2004-02-19 US disclosed
EP-0811629-B1 OPTICALLY ACTIVE BIDENTATE PHOSPHINE LIGAND/PALLADIUM COMPLEX NISSAN CHEMICAL IND LTD (JP) 2003-05-02 EP disclosed
US-5880301-A CATALYSTS FOR PREPARATION OF OPTICALLY ACTIVE BETA-HYDROXYKETONES NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1999-03-09 US disclosed
EP-0811629-A1 OPTICALLY ACTIVE BIDENTATE PHOSPHINE LIGAND/PALLADIUM COMPLEX NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1997-12-10 EP disclosed
EP-0384517-A2 Copolymers of carbon monoxide SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) 1990-08-29 EP disclosed
EP-0354845-A1 Bimetallic bridged platinum hydrides, process for their preparation and their use in catalytic chemical reactions ELF ATOCHEM S.A. (FR) 1990-02-14 EP disclosed
EP-0083158-B1 NOVEL ALDEHYDES AND PROCESS FOR PRODUCING THE SAME TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1985-08-07 EP disclosed
EP-0083158-A1 Novel aldehydes and process for producing the same TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1983-07-06 EP disclosed
US-4370258-A PLATINUM CATALYST, INB METAL HALIDE ASSISTANT CATALYST AND BIDENTATE LIGAND PROMOTER AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1983-01-25 US disclosed
US-4358621-A CATALYTIC HYDROFORMYLATION OF OLEFIN TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) 1982-11-09 US disclosed
EP-0039830-A1 Process for the preparation of optically active compounds and their use in the preparation of vitamin E BASF Aktiengesellschaft (DE) 1981-11-18 EP disclosed
US-4237072-A HYDROGENATION IN THE PRESENCE OF A RHODIUM CHIRAL PHOSPHINE COMPLEX FORMED IN SITU RHONE-POULENC INDUSTRIES (FR) 1980-12-02 US disclosed
US-4229381-A HYDROFORMYLATION OF OLEFINS; PLATINUM CATALYST; BIDENTATE LIGAND AGENCY OF INDUSTRIAL SCIENCE & TECHNOLOGY (JP) 1980-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034080-A1 Method for producing 3,3-diarylpropylamines HNMT, CYP1A1, HRH3 KEAP1 555/4885NFE2L2 385/4885CYP2D6 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.